Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May;36(5):488-492.
doi: 10.1038/s41371-021-00636-y. Epub 2021 Nov 12.

Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection

Affiliations
Review

Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection

Biplab K Maiti. J Hum Hypertens. 2022 May.

Abstract

The recombinant soluble human angiotensin-converting enzyme 2 (rshACE2) is a promising therapy against SARS-CoV-2 infection, but it has some drawbacks that reduce the success of its clinical applications. The bioengineered ACE2 (Tag-sACE2 and probiotic-ACE2) as a way may overcome its therapeutic limitations against ongoing current pandemic.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Dual role of ACE2.
Cartoon represents the dual role of ACE2:virus receptor domain (dark black color ribbon) and lung protector catalytic Zn-site (black dotted circle). The ACE2 structure is adopted from PDB-1R42.
Fig. 2
Fig. 2. ACE2 shedding and virus entry & spreading in cell.
Cartoon represents the proposed ACE2 shedding and SARS-CoV-2 entry as well as randomly circulating sACE2-ASRS-CoV-2 complex in extracellular space.
Fig. 3
Fig. 3. Bioengineered ACE2: Panel A - rsACE2, Panel B - Tag-rsACE2 and Panel C - Probiotic-ACE2.
Probable designed ACE2 for disruption of mACE2-viral interlock: rhACE2 (A), tag-rsACE2 (B), and expression of mACE2 in probiotic (C).

Similar articles

Cited by

References

    1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–207. doi: 10.1056/NEJMoa2001316. - DOI - PMC - PubMed
    1. Gordon DE, Jang GH, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;538:459–68. doi: 10.1038/s41586-020-2286-9. - DOI - PMC - PubMed
    1. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215–20. doi: 10.1038/s41586-020-2180-5. - DOI - PubMed
    1. Guy JL, Lambert DW, Warner FJ, Hooper NM, Turner AJ. Membrane-associated zinc peptidase families: Comparing ACE and ACE2. Biochim Biophys Acta. 2005;1751:2–8. doi: 10.1016/j.bbapap.2004.10.010. - DOI - PMC - PubMed
    1. Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer RA, Stahl M, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181:905–13. doi: 10.1016/j.cell.2020.04.004. - DOI - PMC - PubMed